nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2C8—Mometasone—systemic scleroderma	0.184	0.272	CbGbCtD
Levomilnacipran—ABCB1—Lisinopril—systemic scleroderma	0.084	0.125	CbGbCtD
Levomilnacipran—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0731	0.108	CbGbCtD
Levomilnacipran—ABCB1—Captopril—systemic scleroderma	0.0629	0.0932	CbGbCtD
Levomilnacipran—CYP2D6—Captopril—systemic scleroderma	0.0592	0.0879	CbGbCtD
Levomilnacipran—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0495	0.0734	CbGbCtD
Levomilnacipran—CYP2C19—Prednisone—systemic scleroderma	0.049	0.0727	CbGbCtD
Levomilnacipran—ABCB1—Prednisone—systemic scleroderma	0.0396	0.0587	CbGbCtD
Levomilnacipran—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0297	0.044	CbGbCtD
Levomilnacipran—CYP3A4—Prednisone—systemic scleroderma	0.0237	0.0352	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—systemic scleroderma	0.0199	0.0294	CbGbCtD
Levomilnacipran—CYP2J2—artery—systemic scleroderma	0.000706	0.279	CbGeAlD
Levomilnacipran—CYP2J2—blood vessel—systemic scleroderma	0.00055	0.218	CbGeAlD
Levomilnacipran—Insomnia—Leflunomide—systemic scleroderma	0.000428	0.00132	CcSEcCtD
Levomilnacipran—Abdominal distension—Prednisone—systemic scleroderma	0.000427	0.00132	CcSEcCtD
Levomilnacipran—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000427	0.00132	CcSEcCtD
Levomilnacipran—Paraesthesia—Leflunomide—systemic scleroderma	0.000425	0.00131	CcSEcCtD
Levomilnacipran—Chest pain—Lisinopril—systemic scleroderma	0.000424	0.00131	CcSEcCtD
Levomilnacipran—Anxiety—Lisinopril—systemic scleroderma	0.000422	0.00131	CcSEcCtD
Levomilnacipran—Dyspnoea—Leflunomide—systemic scleroderma	0.000422	0.0013	CcSEcCtD
Levomilnacipran—Hypotension—Mycophenolic acid—systemic scleroderma	0.000421	0.0013	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000421	0.0013	CcSEcCtD
Levomilnacipran—Dyspepsia—Leflunomide—systemic scleroderma	0.000416	0.00129	CcSEcCtD
Levomilnacipran—Vomiting—Mometasone—systemic scleroderma	0.000415	0.00128	CcSEcCtD
Levomilnacipran—Dry mouth—Lisinopril—systemic scleroderma	0.000414	0.00128	CcSEcCtD
Levomilnacipran—Rash—Mometasone—systemic scleroderma	0.000412	0.00127	CcSEcCtD
Levomilnacipran—Asthenia—Captopril—systemic scleroderma	0.000412	0.00127	CcSEcCtD
Levomilnacipran—Dermatitis—Mometasone—systemic scleroderma	0.000411	0.00127	CcSEcCtD
Levomilnacipran—Decreased appetite—Leflunomide—systemic scleroderma	0.000411	0.00127	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000409	0.00127	CcSEcCtD
Levomilnacipran—Headache—Mometasone—systemic scleroderma	0.000409	0.00127	CcSEcCtD
Levomilnacipran—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000409	0.00126	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000408	0.00126	CcSEcCtD
Levomilnacipran—Insomnia—Mycophenolic acid—systemic scleroderma	0.000408	0.00126	CcSEcCtD
Levomilnacipran—Fatigue—Leflunomide—systemic scleroderma	0.000408	0.00126	CcSEcCtD
Levomilnacipran—Pruritus—Captopril—systemic scleroderma	0.000406	0.00126	CcSEcCtD
Levomilnacipran—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000405	0.00125	CcSEcCtD
Levomilnacipran—Constipation—Leflunomide—systemic scleroderma	0.000404	0.00125	CcSEcCtD
Levomilnacipran—Infection—Lisinopril—systemic scleroderma	0.000404	0.00125	CcSEcCtD
Levomilnacipran—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000402	0.00124	CcSEcCtD
Levomilnacipran—Somnolence—Mycophenolic acid—systemic scleroderma	0.000401	0.00124	CcSEcCtD
Levomilnacipran—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000401	0.00124	CcSEcCtD
Levomilnacipran—Shock—Lisinopril—systemic scleroderma	0.0004	0.00124	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000398	0.00123	CcSEcCtD
Levomilnacipran—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000397	0.00123	CcSEcCtD
Levomilnacipran—Neutropenia—Prednisone—systemic scleroderma	0.000397	0.00123	CcSEcCtD
Levomilnacipran—Tachycardia—Lisinopril—systemic scleroderma	0.000396	0.00123	CcSEcCtD
Levomilnacipran—Abdominal pain—Azathioprine—systemic scleroderma	0.000396	0.00122	CcSEcCtD
Levomilnacipran—Body temperature increased—Azathioprine—systemic scleroderma	0.000396	0.00122	CcSEcCtD
Levomilnacipran—Skin disorder—Lisinopril—systemic scleroderma	0.000395	0.00122	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000393	0.00121	CcSEcCtD
Levomilnacipran—Diarrhoea—Captopril—systemic scleroderma	0.000392	0.00121	CcSEcCtD
Levomilnacipran—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000392	0.00121	CcSEcCtD
Levomilnacipran—Irritability—Methotrexate—systemic scleroderma	0.000392	0.00121	CcSEcCtD
Levomilnacipran—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000391	0.00121	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Prednisone—systemic scleroderma	0.000391	0.00121	CcSEcCtD
Levomilnacipran—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00039	0.00121	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000389	0.0012	CcSEcCtD
Levomilnacipran—Fatigue—Mycophenolic acid—systemic scleroderma	0.000389	0.0012	CcSEcCtD
Levomilnacipran—Nausea—Mometasone—systemic scleroderma	0.000388	0.0012	CcSEcCtD
Levomilnacipran—Anorexia—Lisinopril—systemic scleroderma	0.000387	0.0012	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000387	0.0012	CcSEcCtD
Levomilnacipran—Constipation—Mycophenolic acid—systemic scleroderma	0.000386	0.00119	CcSEcCtD
Levomilnacipran—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000385	0.00119	CcSEcCtD
Levomilnacipran—Weight decreased—Prednisone—systemic scleroderma	0.000384	0.00119	CcSEcCtD
Levomilnacipran—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000383	0.00119	CcSEcCtD
Levomilnacipran—Hypotension—Lisinopril—systemic scleroderma	0.00038	0.00117	CcSEcCtD
Levomilnacipran—Dizziness—Captopril—systemic scleroderma	0.000379	0.00117	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000379	0.00117	CcSEcCtD
Levomilnacipran—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000378	0.00117	CcSEcCtD
Levomilnacipran—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000377	0.00116	CcSEcCtD
Levomilnacipran—Urticaria—Leflunomide—systemic scleroderma	0.000376	0.00116	CcSEcCtD
Levomilnacipran—Abdominal pain—Leflunomide—systemic scleroderma	0.000374	0.00116	CcSEcCtD
Levomilnacipran—Body temperature increased—Leflunomide—systemic scleroderma	0.000374	0.00116	CcSEcCtD
Levomilnacipran—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000371	0.00115	CcSEcCtD
Levomilnacipran—Breast disorder—Methotrexate—systemic scleroderma	0.000371	0.00115	CcSEcCtD
Levomilnacipran—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00037	0.00114	CcSEcCtD
Levomilnacipran—Hypersensitivity—Azathioprine—systemic scleroderma	0.000369	0.00114	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000369	0.00114	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000369	0.00114	CcSEcCtD
Levomilnacipran—Insomnia—Lisinopril—systemic scleroderma	0.000367	0.00114	CcSEcCtD
Levomilnacipran—Paraesthesia—Lisinopril—systemic scleroderma	0.000365	0.00113	CcSEcCtD
Levomilnacipran—Vomiting—Captopril—systemic scleroderma	0.000365	0.00113	CcSEcCtD
Levomilnacipran—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000363	0.00112	CcSEcCtD
Levomilnacipran—Dyspnoea—Lisinopril—systemic scleroderma	0.000362	0.00112	CcSEcCtD
Levomilnacipran—Rash—Captopril—systemic scleroderma	0.000362	0.00112	CcSEcCtD
Levomilnacipran—Dermatitis—Captopril—systemic scleroderma	0.000361	0.00112	CcSEcCtD
Levomilnacipran—Somnolence—Lisinopril—systemic scleroderma	0.000361	0.00112	CcSEcCtD
Levomilnacipran—Headache—Captopril—systemic scleroderma	0.000359	0.00111	CcSEcCtD
Levomilnacipran—Dyspepsia—Lisinopril—systemic scleroderma	0.000358	0.00111	CcSEcCtD
Levomilnacipran—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000357	0.0011	CcSEcCtD
Levomilnacipran—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000357	0.0011	CcSEcCtD
Levomilnacipran—Infection—Mycophenolate mofetil—systemic scleroderma	0.000354	0.00109	CcSEcCtD
Levomilnacipran—Decreased appetite—Lisinopril—systemic scleroderma	0.000353	0.00109	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000351	0.00109	CcSEcCtD
Levomilnacipran—Fatigue—Lisinopril—systemic scleroderma	0.00035	0.00108	CcSEcCtD
Levomilnacipran—Shock—Mycophenolate mofetil—systemic scleroderma	0.00035	0.00108	CcSEcCtD
Levomilnacipran—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000349	0.00108	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000349	0.00108	CcSEcCtD
Levomilnacipran—Hypersensitivity—Leflunomide—systemic scleroderma	0.000348	0.00108	CcSEcCtD
Levomilnacipran—Constipation—Lisinopril—systemic scleroderma	0.000347	0.00107	CcSEcCtD
Levomilnacipran—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000347	0.00107	CcSEcCtD
Levomilnacipran—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000346	0.00107	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000344	0.00106	CcSEcCtD
Levomilnacipran—Diarrhoea—Azathioprine—systemic scleroderma	0.000343	0.00106	CcSEcCtD
Levomilnacipran—Nausea—Captopril—systemic scleroderma	0.000341	0.00105	CcSEcCtD
Levomilnacipran—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000339	0.00105	CcSEcCtD
Levomilnacipran—Asthenia—Leflunomide—systemic scleroderma	0.000339	0.00105	CcSEcCtD
Levomilnacipran—Hallucination—Prednisone—systemic scleroderma	0.000338	0.00105	CcSEcCtD
Levomilnacipran—Pruritus—Leflunomide—systemic scleroderma	0.000334	0.00103	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Prednisone—systemic scleroderma	0.000334	0.00103	CcSEcCtD
Levomilnacipran—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000333	0.00103	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000332	0.00103	CcSEcCtD
Levomilnacipran—Dysuria—Methotrexate—systemic scleroderma	0.000332	0.00103	CcSEcCtD
Levomilnacipran—Neutropenia—Methotrexate—systemic scleroderma	0.000332	0.00103	CcSEcCtD
Levomilnacipran—Dizziness—Azathioprine—systemic scleroderma	0.000331	0.00102	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00033	0.00102	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000327	0.00101	CcSEcCtD
Levomilnacipran—Asthenia—Mycophenolic acid—systemic scleroderma	0.000324	0.001	CcSEcCtD
Levomilnacipran—Diarrhoea—Leflunomide—systemic scleroderma	0.000323	0.001	CcSEcCtD
Levomilnacipran—Urticaria—Lisinopril—systemic scleroderma	0.000323	0.000998	CcSEcCtD
Levomilnacipran—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000322	0.000996	CcSEcCtD
Levomilnacipran—Body temperature increased—Lisinopril—systemic scleroderma	0.000321	0.000993	CcSEcCtD
Levomilnacipran—Abdominal pain—Lisinopril—systemic scleroderma	0.000321	0.000993	CcSEcCtD
Levomilnacipran—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00032	0.000989	CcSEcCtD
Levomilnacipran—Pruritus—Mycophenolic acid—systemic scleroderma	0.000319	0.000987	CcSEcCtD
Levomilnacipran—Vomiting—Azathioprine—systemic scleroderma	0.000318	0.000985	CcSEcCtD
Levomilnacipran—Eye disorder—Prednisone—systemic scleroderma	0.000317	0.000982	CcSEcCtD
Levomilnacipran—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000317	0.000982	CcSEcCtD
Levomilnacipran—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000316	0.000979	CcSEcCtD
Levomilnacipran—Rash—Azathioprine—systemic scleroderma	0.000316	0.000977	CcSEcCtD
Levomilnacipran—Dermatitis—Azathioprine—systemic scleroderma	0.000315	0.000976	CcSEcCtD
Levomilnacipran—Flushing—Prednisone—systemic scleroderma	0.000315	0.000975	CcSEcCtD
Levomilnacipran—Headache—Azathioprine—systemic scleroderma	0.000314	0.00097	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000313	0.00097	CcSEcCtD
Levomilnacipran—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000313	0.000969	CcSEcCtD
Levomilnacipran—Dizziness—Leflunomide—systemic scleroderma	0.000313	0.000967	CcSEcCtD
Levomilnacipran—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000309	0.000957	CcSEcCtD
Levomilnacipran—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000309	0.000955	CcSEcCtD
Levomilnacipran—Angiopathy—Prednisone—systemic scleroderma	0.000308	0.000953	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000307	0.000951	CcSEcCtD
Levomilnacipran—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000304	0.000942	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—systemic scleroderma	0.000301	0.000933	CcSEcCtD
Levomilnacipran—Vomiting—Leflunomide—systemic scleroderma	0.000301	0.00093	CcSEcCtD
Levomilnacipran—Hypersensitivity—Lisinopril—systemic scleroderma	0.000299	0.000926	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000299	0.000925	CcSEcCtD
Levomilnacipran—Dizziness—Mycophenolic acid—systemic scleroderma	0.000298	0.000923	CcSEcCtD
Levomilnacipran—Rash—Leflunomide—systemic scleroderma	0.000298	0.000922	CcSEcCtD
Levomilnacipran—Dermatitis—Leflunomide—systemic scleroderma	0.000298	0.000921	CcSEcCtD
Levomilnacipran—Mental disorder—Prednisone—systemic scleroderma	0.000298	0.00092	CcSEcCtD
Levomilnacipran—Nausea—Azathioprine—systemic scleroderma	0.000297	0.00092	CcSEcCtD
Levomilnacipran—Headache—Leflunomide—systemic scleroderma	0.000296	0.000916	CcSEcCtD
Levomilnacipran—Malnutrition—Prednisone—systemic scleroderma	0.000296	0.000915	CcSEcCtD
Levomilnacipran—Asthenia—Lisinopril—systemic scleroderma	0.000291	0.000902	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000291	0.0009	CcSEcCtD
Levomilnacipran—Pruritus—Lisinopril—systemic scleroderma	0.000287	0.000889	CcSEcCtD
Levomilnacipran—Vomiting—Mycophenolic acid—systemic scleroderma	0.000287	0.000887	CcSEcCtD
Levomilnacipran—Rash—Mycophenolic acid—systemic scleroderma	0.000284	0.00088	CcSEcCtD
Levomilnacipran—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000284	0.000879	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—systemic scleroderma	0.000284	0.000878	CcSEcCtD
Levomilnacipran—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000283	0.000875	CcSEcCtD
Levomilnacipran—Headache—Mycophenolic acid—systemic scleroderma	0.000283	0.000874	CcSEcCtD
Levomilnacipran—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000281	0.00087	CcSEcCtD
Levomilnacipran—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000281	0.00087	CcSEcCtD
Levomilnacipran—Nausea—Leflunomide—systemic scleroderma	0.000281	0.000869	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00028	0.000867	CcSEcCtD
Levomilnacipran—Vision blurred—Prednisone—systemic scleroderma	0.000279	0.000862	CcSEcCtD
Levomilnacipran—Urethral disorder—Methotrexate—systemic scleroderma	0.000278	0.000861	CcSEcCtD
Levomilnacipran—Diarrhoea—Lisinopril—systemic scleroderma	0.000278	0.00086	CcSEcCtD
Levomilnacipran—Agitation—Prednisone—systemic scleroderma	0.000272	0.00084	CcSEcCtD
Levomilnacipran—Dizziness—Lisinopril—systemic scleroderma	0.000269	0.000831	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—systemic scleroderma	0.000268	0.00083	CcSEcCtD
Levomilnacipran—Nausea—Mycophenolic acid—systemic scleroderma	0.000268	0.000829	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—systemic scleroderma	0.000265	0.000821	CcSEcCtD
Levomilnacipran—Syncope—Prednisone—systemic scleroderma	0.000265	0.00082	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—systemic scleroderma	0.000263	0.000815	CcSEcCtD
Levomilnacipran—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000811	CcSEcCtD
Levomilnacipran—Loss of consciousness—Prednisone—systemic scleroderma	0.00026	0.000804	CcSEcCtD
Levomilnacipran—Vomiting—Lisinopril—systemic scleroderma	0.000258	0.000799	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—systemic scleroderma	0.000258	0.000797	CcSEcCtD
Levomilnacipran—Rash—Lisinopril—systemic scleroderma	0.000256	0.000792	CcSEcCtD
Levomilnacipran—Convulsion—Prednisone—systemic scleroderma	0.000256	0.000792	CcSEcCtD
Levomilnacipran—Dermatitis—Lisinopril—systemic scleroderma	0.000256	0.000792	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000256	0.000791	CcSEcCtD
Levomilnacipran—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000255	0.00079	CcSEcCtD
Levomilnacipran—Hypertension—Prednisone—systemic scleroderma	0.000255	0.00079	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—systemic scleroderma	0.000255	0.000788	CcSEcCtD
Levomilnacipran—Headache—Lisinopril—systemic scleroderma	0.000255	0.000787	CcSEcCtD
Levomilnacipran—CYP2J2—skin of body—systemic scleroderma	0.000254	0.101	CbGeAlD
Levomilnacipran—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000779	CcSEcCtD
Levomilnacipran—Anxiety—Prednisone—systemic scleroderma	0.000251	0.000776	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00025	0.000773	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—systemic scleroderma	0.000249	0.000769	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—systemic scleroderma	0.000247	0.000764	CcSEcCtD
Levomilnacipran—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000244	0.000753	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—systemic scleroderma	0.000242	0.000748	CcSEcCtD
Levomilnacipran—Nausea—Lisinopril—systemic scleroderma	0.000241	0.000746	CcSEcCtD
Levomilnacipran—Infection—Prednisone—systemic scleroderma	0.00024	0.000742	CcSEcCtD
Levomilnacipran—Shock—Prednisone—systemic scleroderma	0.000237	0.000734	CcSEcCtD
Levomilnacipran—Nervous system disorder—Prednisone—systemic scleroderma	0.000237	0.000732	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisone—systemic scleroderma	0.000235	0.000728	CcSEcCtD
Levomilnacipran—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000728	CcSEcCtD
Levomilnacipran—Skin disorder—Prednisone—systemic scleroderma	0.000234	0.000725	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Prednisone—systemic scleroderma	0.000233	0.000722	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—systemic scleroderma	0.000233	0.00072	CcSEcCtD
Levomilnacipran—Anorexia—Prednisone—systemic scleroderma	0.00023	0.000711	CcSEcCtD
Levomilnacipran—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000226	0.0007	CcSEcCtD
Levomilnacipran—Rash—Mycophenolate mofetil—systemic scleroderma	0.000224	0.000694	CcSEcCtD
Levomilnacipran—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000224	0.000694	CcSEcCtD
Levomilnacipran—Headache—Mycophenolate mofetil—systemic scleroderma	0.000223	0.00069	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—systemic scleroderma	0.000221	0.000684	CcSEcCtD
Levomilnacipran—Insomnia—Prednisone—systemic scleroderma	0.000218	0.000675	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisone—systemic scleroderma	0.000217	0.00067	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—systemic scleroderma	0.000214	0.000662	CcSEcCtD
Levomilnacipran—Dyspepsia—Prednisone—systemic scleroderma	0.000212	0.000657	CcSEcCtD
Levomilnacipran—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000211	0.000654	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—systemic scleroderma	0.00021	0.000651	CcSEcCtD
Levomilnacipran—Decreased appetite—Prednisone—systemic scleroderma	0.00021	0.000649	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000209	0.000646	CcSEcCtD
Levomilnacipran—Fatigue—Prednisone—systemic scleroderma	0.000208	0.000644	CcSEcCtD
Levomilnacipran—Constipation—Prednisone—systemic scleroderma	0.000206	0.000638	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—systemic scleroderma	0.0002	0.00062	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—systemic scleroderma	0.000198	0.000612	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000197	0.000611	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000197	0.00061	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—systemic scleroderma	0.000196	0.000606	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000195	0.000603	CcSEcCtD
Levomilnacipran—CYP2J2—tendon—systemic scleroderma	0.000194	0.0767	CbGeAlD
Levomilnacipran—Anorexia—Methotrexate—systemic scleroderma	0.000192	0.000595	CcSEcCtD
Levomilnacipran—Urticaria—Prednisone—systemic scleroderma	0.000192	0.000593	CcSEcCtD
Levomilnacipran—Abdominal pain—Prednisone—systemic scleroderma	0.000191	0.00059	CcSEcCtD
Levomilnacipran—Body temperature increased—Prednisone—systemic scleroderma	0.000191	0.00059	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—systemic scleroderma	0.000188	0.000583	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—systemic scleroderma	0.000182	0.000564	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—systemic scleroderma	0.000181	0.00056	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—systemic scleroderma	0.00018	0.000556	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—systemic scleroderma	0.000179	0.000555	CcSEcCtD
Levomilnacipran—Hypersensitivity—Prednisone—systemic scleroderma	0.000178	0.00055	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—systemic scleroderma	0.000177	0.000549	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—systemic scleroderma	0.000175	0.000542	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000174	0.000539	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—systemic scleroderma	0.000174	0.000538	CcSEcCtD
Levomilnacipran—Asthenia—Prednisone—systemic scleroderma	0.000173	0.000536	CcSEcCtD
Levomilnacipran—Pruritus—Prednisone—systemic scleroderma	0.000171	0.000528	CcSEcCtD
Levomilnacipran—CYP2J2—lung—systemic scleroderma	0.00017	0.0673	CbGeAlD
Levomilnacipran—Diarrhoea—Prednisone—systemic scleroderma	0.000165	0.000511	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000165	0.00051	CcSEcCtD
Levomilnacipran—Urticaria—Methotrexate—systemic scleroderma	0.00016	0.000496	CcSEcCtD
Levomilnacipran—Dizziness—Prednisone—systemic scleroderma	0.00016	0.000494	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—systemic scleroderma	0.000159	0.000493	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—systemic scleroderma	0.000159	0.000493	CcSEcCtD
Levomilnacipran—Vomiting—Prednisone—systemic scleroderma	0.000153	0.000475	CcSEcCtD
Levomilnacipran—Rash—Prednisone—systemic scleroderma	0.000152	0.000471	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisone—systemic scleroderma	0.000152	0.00047	CcSEcCtD
Levomilnacipran—Headache—Prednisone—systemic scleroderma	0.000151	0.000468	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—systemic scleroderma	0.000149	0.00046	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—systemic scleroderma	0.000145	0.000448	CcSEcCtD
Levomilnacipran—Nausea—Prednisone—systemic scleroderma	0.000143	0.000443	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—systemic scleroderma	0.000143	0.000441	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—systemic scleroderma	0.000138	0.000427	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—systemic scleroderma	0.000133	0.000412	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—systemic scleroderma	0.000128	0.000397	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—systemic scleroderma	0.000127	0.000393	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—systemic scleroderma	0.000127	0.000393	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—systemic scleroderma	0.000126	0.000391	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—systemic scleroderma	0.00012	0.000371	CcSEcCtD
Levomilnacipran—SLC6A4—digestive system—systemic scleroderma	0.00011	0.0435	CbGeAlD
Levomilnacipran—ABCB1—blood vessel—systemic scleroderma	0.000103	0.0407	CbGeAlD
Levomilnacipran—SLC6A4—lung—systemic scleroderma	9.17e-05	0.0363	CbGeAlD
Levomilnacipran—CYP2C19—digestive system—systemic scleroderma	9.09e-05	0.036	CbGeAlD
Levomilnacipran—SLC6A2—lung—systemic scleroderma	8.07e-05	0.032	CbGeAlD
Levomilnacipran—CYP3A4—digestive system—systemic scleroderma	5.38e-05	0.0213	CbGeAlD
Levomilnacipran—CYP2D6—digestive system—systemic scleroderma	5.29e-05	0.021	CbGeAlD
Levomilnacipran—ABCB1—digestive system—systemic scleroderma	3.81e-05	0.0151	CbGeAlD
Levomilnacipran—ABCB1—lung—systemic scleroderma	3.18e-05	0.0126	CbGeAlD
